NCT05630326 (ABCUCEOI) is a clinical trial of comparing, prevalence in Renal Insufficiency, sponsored by Hamad Medical Corporation.

Who is sponsoring NCT05630326?

NCT05630326 is sponsored by Hamad Medical Corporation.

What drugs are being tested in NCT05630326?

Interventions in NCT05630326: comparing, prevalence, assessment, association, evaluation.

What condition does NCT05630326 study?

NCT05630326 studies Renal Insufficiency.

Is NCT05630326 still recruiting?

NCT05630326 is currently completed. Last updated 27 July 2023.

Last reviewed 2023-07-27 · How we verify

NCT05630326: ABCUCEOI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between COVID-19 and UTIs Caused by ESBL Organism in Infants

Completed Last updated 27 July 2023

What this trial tests

trial testing comparing, prevalence in Renal Insufficiency in 5,600 participants. Completed in 20 July 2023.

Timeline

1 March 2023

Primary endpoint
1 July 2023

20 July 2023

Quick facts

Lead sponsor	Hamad Medical Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5,600
Start date	1 March 2023
Primary completion	1 July 2023
Estimated completion	20 July 2023
Sites	1 location across Qatar

Drugs / interventions tested

comparing, prevalence
assessment
association
evaluation

Conditions studied

Renal Insufficiency — all drugs for Renal Insufficiency →

Sponsor

Hamad Medical Corporation — full company profile →

Who can join

Under 1, any sex, with Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Urinary tract infections (UTIs) in infants and young children are one of the most common bacterial infections, usually febrile illness without source, frequently due to Enterobacteriaceae, mainly Escherichia coli. Multidrug-resistant organisms including extended-spectrum beta-lactamase (ESBL) producing bacteria are becoming more prevalent. Due to the risk factors of ESBL-producing organisms in community-acquired (CA)-UTIs in infants in QATAR and Arab countries are still not studied because of the limited therapeutic options. hence, the importance of this study is to get knowledge about how to decrease the rapidly increasing in ESBL- producing bacteria, in infants, and to use antibiotics in a suitable guideline.so, The aim of this retrospective case-control study is to determine the clinical manifestations, and investigations of urinary tract infections among infants and the association with COVID-19 infection, in pediatric emergency centers at Hamad General Hospital - Qatar. From 1st January 2015 till 1st January 2022.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Renal Insufficiency

Currently open trials in the same condition.

NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT07001436 — A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insuffici · Phase 1 · recruiting
NCT06431789 — Prospective Observational Association Between SLCO1B1 Gene Polymorphism and the Anti-factor Xa Activity of Edoxaban in P · recruiting
NCT06354231 — DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC · Phase 2 · recruiting
NCT05428631 — Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients with Ca · NA · recruiting

Other Hamad Medical Corporation trials

Trials by the same sponsor.

NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05630326 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
Last refreshed: 27 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05630326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing